Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PPS of $500 at least IMO.
Have you ever looked at the potential sales in Sorrento's COVID, PAIN and CANCER and INFLAMMATION portfolios two or three years from now? Make your own judgements. Here are mine.
1. COVID
COVISTIX, COVIDROPS, COVIMSC etc... and second generation booster vaccines and anti-virals. Revenues begin this year. Annual Sales of at least $10 Billion.
2. PAIN
SP-102, SP-103, SP-104 target huge sciatica, back pain and Covid long hauler markets. RTX in Cancer and Arthritic pain. Revenues begin in 2H of 2022. Annual Sales of at least $15 Billion.
3. CANCER + INFLAMMATION
ABIVERTINIB in NSCLC and other solid tumours, and against cytokine storm, lupus and MS. At least 12 ADNAB(Mayo Clinic) indications and dozens of CAR-T, DAR-T and other drugs. Sofusa lymphatic drug delivery system. Revenues begin in 2022. Annual Sales of at least $20 Billion.
Potential market Cap? Multi-Billions!
Merck claims that their anti-viral pill is about 50% effective in preventing hospitalizations and deaths in Covid patients. How might COVIDROPS compare? We have no COVIDROPS published data but competitor Mabs are about 80% effective and Sorrento has suggested that COVIDROPS might improve on that! However competitor Mabs are very expensive and require several hours for infusion in overcrowded infusion centers. COVIDROPS could be administered in a few minutes in the doctors office, the pharmacy or even at home.
What are COVIDROPS advantages compared to competitor Mabs?
1. COVIDROPS efficacy may significantly exceed 80%.
2. They only require 1/50th of the dosage of competitor Mabs. This smaller dosage reduces cost and potential negative adverse events.
3. They can be produced using the the C1 technology. This allows for production runs producing 10 times the quantity of the competitors production adding even more cost savings!
4. They do not require costly hospital or infusion center time.
Just as COVISTIX was first approved in Mexico and will likely be approved next in Brazil, Canada, the UK and Europe, we should expect the same for COVIDROPS. Dr.Ji has stated that they plan to speed up trials in the US by working directly with State governments.
I look forward to international marketing partnerships and worldwide multi-Billion sales!
So if the Merck pill is 50% effective...
and we learn that Abivertinib is 60-70% effective...
and COVIDROPS is 95-98% effective? We should soon hear about both!
Good point. I found the discussion between Dr.Ji and the DYAI CEO was very enlightening and encouraging.
$60 buyout offer would be a joke! $600 in several years is highly possible.
* SP102, 103 and 104 and RTX will bring in multi-Billions
* Abivertinib, ADNAB drugs and DAR-T drugs will bring in multi-Billions
* COVISTIX,COVIDROPS,antibody and vaccine cocktails will be equally big
Pain,Cancer and Covid variants are not going away.
WORLDWIDE LONG-TERM NEED FOR ALL SORRENTO PROGRAMS!
I expect COVISTIX revenue to start soon and increase steadily over the next 12 months. I also expect COVIDROPS revenue as early as Q1 or Q2 2022. And I expect ABIVERTINIB and SP102 revenue within the next 9 months. The annual revenue from these 4 technologies will be in the multi-Billions. And if I am even close in these expectations, we are looking at a triple digit share price!
Could be! Need trials....even if it starts off-label. And how about Abivertinib in MS and Lupus...two huge indications!
At Benzinga Dr.Ji said Sorrento now has $300 million in cash and holdings and in several years is aiming for a $200-400 Billion market cap company. You can listen at
I hope everyone listened to the Benzinga panel where Dr.Ji and the CEO of DYAI discussed the advantage of using the C1 technology to produce anti-Covid antibodies.
Dr. Ji pointed out that compared to the Regeneron antibody Sorrento's CoviDrop antibody needed only 1/50th of the dose. Using the C1 technology Sorrento can produce 10 times as much antibody per run as conventional technologies. So put that together and Sorrento has a 500 fold production cost advantage over competitors!
Furthermore, Sorrento antibodies (all 3!) cover all current and potential future variants!
SORRENTO HAS CHEAPER AND MORE EFFECTIVE ANTIBODIES! Trials in US, UK and Brazil are already underway...and are being accelerated!
4 highlights from this morning.
* SP102 news is outstanding. Marketing as early as mid 2022. Sales potential $10 Billion.
* STIX and COVIDROPS are progressing rapidly...Mexico, Brazil, Canada, UK and US states need the tests and antibodies! Huge sales potential in coming months.
* Two new second generation vaccines to head off new variants and provide more effective longer lasting booster shots!
* Dozens of best in class cancer drugs. Abivertinib leading the way!
Henry still aiming for $200-400 Billion market Cap in 3-5 years...and I trust him!
The market is down because of Covid! I can think of 18 Covid related tests, antibodies and drugs in development by Sorrento! When the market wakes up, Sorrento will soar!
1.COVITRACE™ (Diagnostic Test for the Detection of SARS-CoV-2 in Nasal Swab and Saliva)
2.COVISTIX™ (Antigen Test for the Detection of SARS-CoV-2 Virus in Nasal Swab)Mexico EUA APPROVED
3.COVITRACK™ Platinum (Antibody Test for the Detection of Antibodies to SARS-CoV-2 in Blood)
4.COVIGUARD™ (Neutralizing Antibody – STI 1499)
5.COVI-AMG™ (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020)
6.COVIDROPS™ (Intranasal COVI-AMG Neutralizing Antibody – STI 2099)
7.COVISHIELD™ (Neutralizing Antibody Cocktail)
8.COVIDTRAP™ (ACE2 Receptor Decoy – STI 4398)
9.ABIVERTINIB (Cytokine Storm – STI 5656)
10.SALICYN-30 (Anti-viral – STI 2030)
11.COVI-MSC (Acute Respiratory Distress Syndrome – STI 8282)
12.ARK-301 long-haul Covid symptoms
13.mRNA-based multivalent vaccine
14.low cost C1 based multivalent vaccine(rights to 60% of world population)
15.MP18 oral antiviral MPro inhibitor
16.Combination oral antiviral drug cocktail
17.RESPISTIX Combination Covid/seasonal flu tests
18.Combination Covid/seasonal flu vaccines
Sept.29 is WEDNESDAY!
Thursday September 29, 2021 is a busy day for Sorrento. 2 presentations!
CANTOR 9:20 ET
BENZINGA 11:30 ET
Can we expect news on Wednesday or will it be held until Thursday morning?
That draft ad is aimed at an english speaking audience (US in my opinion!). I expect an US launch very soon. And I think it is very well done!
Here are some of the top portfolio items we might see updated at this weeks 2 presentations. Updates on STIX / ABI / SP102 / DROPS could be highlights IMO!
COVITRACE™ (diagnostic) Diagnostic Test
FDA Emergency Use Authorization (EUA) Application Expected
COVISTIX™ (diagnostic) Antigen Test
FDA Emergency Use Authorization (EUA) Application Submitted
COVITRACK™ – Platinum (diagnostic) Next Generation Antibody Test
In final manufacturing and clinical testing
*
COVIGUARD™ (treatment) Neutralizing Antibody (IV) in Inpatients
*
COVI-AMG™ (treatment) Neutralizing Antibody (IV) in Outpatients
*
COVIDROPS™ (treatment) Neutralizing Antibody (Intranasal) in Outpatients
*
COVISHIELD™ (treatment) Neutralizing Abs (IV) in Inpatients
*
COVIDTRAP™ (treatment) ACE2 Receptor Decoy (IV) in Inpatients
*
ABIVERTINIB (treatment) Severe or Critical COVID-19 in ICU Patients
*
SALICYN – 30 (treatment) Anti-viral
*
COVI-MSC (treatment) ARDS due to COVID-19 in ICU Pts
*
Immunotherapy
CD38 CAR-T Multiple Myeloma
*
CD38 DAR-T Multiple Myeloma
*
CD38 ADC Amyloidosis
*
Seprehvir™ Solid Tumors
*
Seprehvec™ Solid Tumors
*
ABIVERTINIB NSCLC
*
ADNIC Solid and Liquid Tumors
*
Pain
SP-102 back and sciatic pain
*
RTX (resiniferatoxin)
Epidural route Intractable Pain in Advanced Cancer
*Orphan designation
RTX (resiniferatoxin)
Intra-articular route Moderate to Severe OA
*
Lymphatic Delivery
Sofusa® anti-TNF Autoimmune
*
Sofusa® anti-PD-1 CTCL
*
News next week?
Sorrento Upcoming Events
Sep 27 - Sep 29, 2021
2021 Cantor Virtual Global Healthcare Conference
Benzinga Healthcare SmallCap
Wednesday Sept. 29, 11:30 AM
SORRENTO Upcoming Events
Sep 27 - Sep 29, 2021
2021 Cantor Virtual Global Healthcare Conference
STIX / ABIVERTINIB / SP102 / DROPS
All have near term news. All have billion dollar markets.
The other 72+ Sorrento programs can be financed by the profits from these 4 programs alone. I was glad to see the new updated corporate presentation. https://investors.sorrentotherapeutics.com/static-files/da3ae428-94af-47fc-b20f-5cab2e10b54e.
***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico...25million shipped!)DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential as soon as August
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has millions of shares of ImmunityBio, Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration will be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's will produce revenues within weeks(Mexico)as 25 million testkits are being shipped. And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
s
.
STIX / ABIVERTINIB / SP102 / DROPS
Remember these four.
All have near term news.
All have billion dollar markets.
The other 65 Sorrento programs can be financed by the profits from these 4 programs.
They are the point of the spear!
2022 will be a great year for Sorrento. Why?
Two programs. Abivertinib(cancer) and SP-102(pain).
Both will be multi-Billion dollar sales programs!
But what about the Covid programs?
Covi-Stix has received its first EUA and sales will soon be reported.
Covid is not going away...Covi-AMG, Covi-Drops, Abivertinib(ARDS), Covi-MSC and the anti-virals and second generation vaccines will be needed.
Sorrento's connections with DARPA and the NAVY will pay off.
Aircraft carriers and submarines cannot afford Covid outbreaks.
Sorrento has the worlds largest anti-Covid portfolio. It will be needed and I look forward to worldwide marketing partnerships being announced.
All the best to all the longs!
I was glad to see the new updated corporate presentation. I like our chances! https://investors.sorrentotherapeutics.com/static-files/da3ae428-94af-47fc-b20f-5cab2e10b54e.
***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico...25million shipped!)DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential as soon as August
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has 8.2 million shares of ImmunityBio, 20.4 million shares of Celularity and 35% of ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration will be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's will produce revenues within weeks(Mexico)as 25 million testkits are being shipped. And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
I expect partnership(s) rather than a buyout. Within days we could hear of Chinese marketing approval for ABIVERTINIB in NSCLC and Brazilian and US EAU approval for preventing Covid cytokine storm!
On June 2, 2021 , over three months ago, Sorrento issued a press release stating, "Sorrento is seeking major global partnership(s) to co-develop and co-commercialize ABIVERTINIB." Such a partnership would presumably cover not only NSCLC and the Covid application but also many other cancers and autoimmune diseases.
ABIVERTINIB has blockbuster applications to many indications. Any partnership(s) would be worth many hundreds of millions. The worldwide Covid EUA approvals in themselves would be a game-changer! Have you ever seen a share price go down just before big news? I have!
Top 3 Institutional Holders..,about 15% of company. What do they know?
Blackrock Inc. 19,117,922 shares as of Jun 29, 2021. 6.41% worth $185,252,664
Vanguard Group 14,129,991 shares as of Jun 29, 2021. 4.74% worth $136,919,612
State Street 10,232,527 shares as of Jun 29, 2021. 3.43% worth $99,153,186
I am glad to see Sorrento advancing its cutting edge Covid programs in Brazil, Mexico, the UK and the US with DoD support. They will help defeat the current pandemic and prepare to get ahead of future pandemics. I hope this will gain bi-partisan support!
9/3 The White House wants $65 billion for an ‘Apollo’-style pandemic preparedness program
WASHINGTON — The Biden administration on Friday unveiled a sweeping new biosecurity plan, outlining a $65 billion proposal to remake the nation’s pandemic preparedness infrastructure in the wake of Covid-19.
The new spending would represent one of the largest investments in public health in American history: During a press briefing, Eric Lander, the White House science adviser, likened the proposal to the Apollo program of the late 1960s.
The immense funding boost would target programs aimed at developing and manufacturing vaccines, treatments, and tests more quickly. It would also provide new money for laboratory capacity, viral detection mechanisms, and early warning systems.
“For the first time in the nation’s history, due to these types of advancements in scientific technology, we have the opportunity not just to refill stockpiles but to transform our capabilities,” Lander said. “But we really need to start preparing now.”
Indeed, the White House funding request comes with a near-term deadline. While the spending would be spread over the coming seven to 10 years, it also includes an ask for at least $15 billion to be included within a forthcoming, $3.5 trillion budget plan still pending on Capitol Hill. The White House is still in discussions with Congress, Lander said, but he was “very optimistic” that lawmakers would agree to the request.
The new spending would target a wide array of new pandemic preparedness capabilities. It would include over $24 billion for vaccine infrastructure, with a goal of beginning to manufacture vaccine doses meant to protect against any virus family within 100 days of a pandemic threat first emerging.
The plan would include nearly $12 billion to develop — and have on hand — a range of treatments available for any known virus family even before a particular pathogen emerged as a pandemic threat.
It would also provide $5 billion for diagnostics that the government would aim to make available within weeks of identifying a new biosecurity threat.
“What this plan is about is ensuring the United States has the capabilities it needs to operationalize [its response] when we see the first signs of an emerging outbreak that could have epidemic or pandemic potential,” Beth Cameron, the top biosecurity expert on the National Security Council, said during the briefing.
It’s not yet clear how Congress will respond to the Biden administration’s sweeping proposal, which expands on a previous request to spend $30 billion over four years on improving future pandemic prevention and preparedness. In a subsequent version of Democrats’ budget bill, however, lawmakers included just $5 billion, drawing criticism from many public health experts who said the government was repeating the same mistakes that led to the country’s chaotic response to Covid-19.
The $65 billion proposal doesn’t stop at treatments, tests, and vaccines.
It would include $3.1 billion aimed at establishing an early-warning system for new disease outbreaks, including systems to sequence pathogens found in wastewater and a “reliable clinical surveillance system.” Biden also calls for spending to help reduce health inequity, fund lab capacity, and improve public health communication. He also wants to put money toward developing better protective equipment for health workers and creating better systems for “pathogen protection,” like better ventilation systems and surface cleaners.
The plan also includes measures to ensure that research and development “involving potentially dangerous biological agents is conducted safely and securely, by fostering a global research environment that adopts and enforces high standards.” The lab-safety provisions are a potential nod to the unproven theory that Covid-19 originated from “gain-of-function” research performed in a Chinese laboratory, a long-running controversy in U.S. and global politics.
https://www.statnews.com/2021/09/03/biden-wants-65-billion-for-apollo-style-pandemic-preparedness-program/
https://www.whitehouse.gov/wp-content/uploads/2021/09/American-Pandemic-Preparedness-Transforming-Our-Capabilities-Final-For-Web.pdf
I agree with those who say that we should expect ABIVERTINIB news any time now. We may in fact receive at least 4 news releases.
1. We may hear about successful trial results from Brazil and the US in the use of ABIVERTINIB to prevent and treat Covid cytokine storm.
2. This news should be followed by news of EUA approvals around the world.
3. We may also hear about marketing approval for ABIVERTINIB in NSCLC in China.
4. On June 2, 2021 , over three months ago, Sorrento issued a press release stating, "Sorrento is seeking major global partnership(s) to co-develop and co-commercialize ABIVERTINIB." Such a partnership would presumably cover not only the Covid application but also NSCLC, many other cancers and autoimmune diseases.
ABIVERTINIB has blockbuster applications to many indications. Any partnership(s) would be worth many hundreds of millions. The worldwide Covid EUA approvals in themselves would be a game-changer!
Good points 1776! As I am not a patent attorney I don't know...but I do believe Sufusa is often overlooked ...the potential is enormous.
Sorrento Needle-Free Delivery Technology(Sofusa® MuVaxxTM) Designed to Maximize Immunization of Sorrento mRNA and C-1 based vaccines. May increase efficacy while reducing side-effects and costs because dosing can be reduced by 90%!
Lymph nodes are the primary organs for generating adaptive immune responses as dendritic cells activate T and B cells. Thus, delivering therapeutics directly toward lymph nodes (versus most common method of delivery into muscle tissue or blood) presents an opportunity to potentially improve current vaccines. Lymph Nodes provide specialized microenvironment in order to orchestrate immune responses.
The increased efficacy, safety and cost savings apply to vaccines, cancer treatments and anti-inflammatory drugs. We'll be hearing more about Sofusa® MuVaxxTM !
This is why prevention and treatment of cytokine storm(ARDS) is so important...as is the recovery of "long-haulers"!
"It has been found that 40% of patients with COVID-19 develop ARDS, and 20% of ARDS cases are severe. The prevalence of post-COVID-19 fibrosis will become apparent with time, but early analysis from patients with COVID-19 on hospital discharge suggests that more than a third of recovered patients develop fibrotic abnormalities. The pathological feature of ARDS is diffuse alveolar damage (DAD) which is characterized by an initial acute inflammatory exudative phase with hyaline membranes, followed by an organizing phase and fibrotic phase. Previous studies highlight that duration of disease is an important determinant for lung fibrosis post ARDS. This study showed that, 4% of patients with a disease duration of less than 1 week, 24% of patients with a disease duration of between weeks 1 and 3, and 61% of patients with a disease duration of greater than 3 weeks, developed fibrosis."
Glad to see COVIMSC advance in the US and Brazil. And that it is being tested both in "rescuing" people from Covid cytokine storm AND to help the "recovery" of Covid long-haulers. Both are very large unmet needs!
We could get ABIVERTINIB Covid cytokine storm "prevention" results from the US and Brazil later this month. If it is successful it is another enormous unmet need.
The next important treatment news could be about COVIDROPS. These nasal drops would be a treatment game changer. They are undergoing interesting trials in several jurisdictions including the UK.
COVIMSC, ABIVERTINIB and COVIDROPS each have enormous worldwide potential. Each would warrant EUA approvals and would likely attract worldwide marketing partnerships.
These near term results plus the PSS arbitration results and the pivotal SP-102 results make for an interesting Q4 2021 and Q1 2022.
Interesting post by Chuck.
Chuck30 minutes ago
Manufacturing of equipment / devices can be done efficiently and at great advantage using an FTZ approach with Maquiladora (twin plant approach) that enables production in Mexico and some assembly (kitting and packaging) in the US. Not only does this approach deliver benefits in reduced labor, but the Foreign Trade Zone (FTZ) approach enable full access to all markets in NA and Latin America without import / export restrictions, taxes, levies or tariffs.
I have used the FTZ and Maquiladora approach in past production and go-to-market ramp ups and think that if SRNE is going that route then that is a very savvy move! Glad to see manufacturing units in Mexico!
What is a Foreign-Trade Zone?
A foreign-trade zone is a designated location in the United States where companies can use special customs procedures that help encourage U.S. activity and value added – in competition with foreign alternatives – by allowing delayed or reduced duty payments on foreign merchandise, as well as other savings.
A site which has been granted zone status may not be used for zone activity until the site has been separately approved for FTZ activation by local U.S. Customs and Border Protection (CBP) officials, and the zone activity remains under the supervision of CBP. FTZ sites and facilities remain within the jurisdiction of local, state or federal governments or agencies.
What is a maquiladora?
A maquiladora is a manufacturing operation or factory in Mexico, usually near the US-Mexico border, that acquires raw and/or semi-finished materials from a foreign principal and manufactures or assembles a finished product, which will then be exported back to the principal. The owner – the maquiladora principal – is usually located in the United States. Essentially, the maquiladora provides manufacturing services to its principal, and the foreign principal is the owner of the inventory, machinery and equipment.
Besides the economic advantages of competitive manufacturing costs, maquiladoras have significant tax advantages, in particular a statutory permanent establishment (PE) exemption. Under this exemption, a maquiladora does not constitute a PE for Mexican tax purposes, and corporate income taxes are essentially based on a small percentage of the production capital (total value of the assets or cost and expenses). In addition, there are significant duty and tariff exemptions in both Mexico and the US, as well as substantial VAT benefits, payroll tax and social security benefits, and overall TP certainty for manufacturing operations through safe harbor or APA."
Please ignore my last post....wrong year!
Sorrento presentation The LD 500
Thursday Sept. 3, 2021
12:40 Eastern time
Sorrento has 3 amazing portfolios. Covid. Pain. Cancer.
1. COVID. Sorrento has 18 programs in its Covid portfolio. It has the largest Covid portfolio in the world. Revenues from the Mexico EUA will accrue this year. COVISTIX, COVIDROPS, COVIMSC, ABIVERTINIB(COVID) could receive EUA's in coming months. RESPISTIX, C1 VACCINE and mRNA VACCINE have a longer timeline but broader tests and booster vaccines are clearly needed.
2. PAIN. SP-102 Pivotal phase 3 results due any day now. Lower back pain and sciatica market is $5-6 Billion. Revenue expected in 2022. RTX in cancer and arthritic pain also has enormous potential. Current non-opioid pain revenue is already nearing $100 million.
3. CANCER. ABIVERTINIB(NSCLC) approval is close in China. Both ADNAB(MAYO CLINIC) and DAR-T each have over a dozen potential targets. And CAR-T and ADC and several IO's are in phase 2.
With hundreds of millions in wise investments, rapidly increasing revenue streams and many potential worldwide marketing partnerships Sorrento is in great shape to reward its current early investors! This is a rare opportunity ... I'm glad I'm able to be part of this!
That is worth a chuckle! Blackrock became the worlds largest asset manager by accident. That's why Fritz earned a spot on my ignore list.
Why does Blackrock(the worlds largest asset management company) hold over 19 million Sorrento shares? Why is the analyst price target $35? Why does Sorrento have the worlds largest Covid portfolio(18) and one of the largest cancer portfolios?
***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico...25million shipped!)DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential as soon as August
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has 8.2 million shares of ImmunityBio, 20.4 million shares of Celularity and 35% of ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration will be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's will produce revenues within weeks(Mexico)as 25 million testkits are being shipped. And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
Why does Blackrock(the worlds largest asset management company) hold 19.4 million Sorrento shares? Why is the analyst price target $30? Why does Sorrento have the worlds largest Covid portfolios and one of the largest cancer portfolios?
Phase 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico...25million shipped!)DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel
13. Cynviloq (part of PSS lawsuit)
Phase 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential as soon as August
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
Phase 1, IND filed or pre-IND (38+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
37. 1,000,000+ small molecule library
38. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has 8.2 million shares of ImmunityBio, 20.4 million shares of Celularity and 35% of ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration will be settled with very large potential gains. And it has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's will produce revenues within weeks(Mexico)as 25 million testkits are being shipped. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
Sorrento is the ONE STOP COVID SHOP! I can think of 18 Covid related tests, antibodies and drugs mentioned by Sorrento!
1.COVITRACE™ (Diagnostic Test for the Detection of SARS-CoV-2 in Nasal Swab and Saliva)
2.COVISTIX™ (Antigen Test for the Detection of SARS-CoV-2 Virus in Nasal Swab)Mexico EUA APPROVED
3.COVITRACK™ Platinum (Antibody Test for the Detection of Antibodies to SARS-CoV-2 in Blood)
4.COVIGUARD™ (Neutralizing Antibody – STI 1499)
5.COVI-AMG™ (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020)
6.COVIDROPS™ (Intranasal COVI-AMG Neutralizing Antibody – STI 2099)
7.COVISHIELD™ (Neutralizing Antibody Cocktail)
8.COVIDTRAP™ (ACE2 Receptor Decoy – STI 4398)
9.ABIVERTINIB (Cytokine Storm – STI 5656)
10.SALICYN-30 (Anti-viral – STI 2030)
11.COVI-MSC (Acute Respiratory Distress Syndrome – STI 8282)
12.ARK-301 long-haul Covid symptoms
13.mRNA-based multivalent vaccine
14.low cost C1 based multivalent vaccine(rights to 60% of world population)
15.MP18 oral antiviral MPro inhibitor
16.Combination oral antiviral drug cocktail
17.RESPISTIX Combination Covid/seasonal flu tests
18.Combination Covid/seasonal flu vaccines
Sorrento is exercising its option on MP18.
MPI8 demonstrated superior antiviral activity in a head-to-head comparison with a late-stage clinical antiviral compound (EIDD-2801).
Based on the IC50 data of the Plague Reduction Neutralization Test (PRNT) of live virus infecting Vero E6 cells, MPI8 demonstrated approximately ten-fold (10x) higher antiviral potency than EIDD-2801 against SARS-CoV-2 and its Alpha (UK) and Delta (Indian) VoCs and three to seven-fold (3-7x) higher antiviral potency against Beta (South Africa, 3X) and Gamma (Brazil/Japan, 6-7X) VoCs.
EIDD-2801 is in a phase 2/3 study by Merck. The US government is committed to purchasing $1.2 billion worth of EIDD-2801 if the current trials are successful.
If MP18 is 3-10 times more effective what will it be worth?